The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
February is National Age-Related Macular Degeneration (AMD) and Low Vision Month. This disease is the leading cause of blindness, and its prevalence is expected to soar as the world’s population ages, leading to an overwhelming projected demand for AMD care by 2050.
A roundtable discussion between leading optometrists led by Dr. Greg Caldwell summarizing current understanding of early stages of AMD, the link to impaired dark adaptation and the benefits of implementing dark adaptation testing into optometric practice.
Recent research has shown that we may be able to identify AMD-affected individuals even earlier by testing for impaired dark adaptation. Learn how this discovery can translate to early detection and intervention of age-related macular degeneration.